Analysis of response of vitiligo to treatment with NBUVB


  • J. Madhava Praveen Meenakshi Medical College and Research Institute, Enathur, Kanchipuram, Tamil Nadu, India
  • Jatin Sidhwa Meenakshi Medical College and Research Institute, Enathur, Kanchipuram, Tamil Nadu, India



Vitiligo, NBUVB, Phototherapy


Background: Vitiligo is an acquired skin disorder characterised by white (depigmented) patches in the skin, due to the loss of functioning melanocytes. The disease can have devastating consequences on an individual’s relationships with others and internal feelings of self-worth. Vitiligo is caused by a dynamic interplay between genetic and environmental risks that initiates an autoimmune attack on melanocytes in the skin. Long term phototherapy has shown good response in the management of vitiligo. In this study we explore the efficacy of phototherapy in management of our vitiligo patients.

Methods: 30 subjects were included in the study. Subjects were started on NBUVB at 300mj/cm2. Weekly 3 doses were given. Doses were increased after every 3rd sitting by 10%. In case of adverse effects treatment is withheld till resolution of symptoms following which NBUVB is given at 50% of the last dose and patient managed based on the response.

Results: A majority of the subjects showed significant and persistent improvement within the first 3 months of initiation of treatment. The proportion of the patients showing improvement increased with duration of treatment.

Conclusions: Our study has revealed the standard and significant role the phototherapy plays in the treatment of vitiligo as a monotherapy or as an adjuvant with other treatment modalities. With good treatment response and minimal side effect incidence, phototherapy is an important treatment modality in the management of vitiligo.



Matin R. Vitiligo in adults and children. BMJ Clin Evid. 2008;2008:1717.

Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73:149–56.

Huggins RH, Schwartz RA and Janniger CK. Vitiligo. Acta Dermatoven APA. 2005;14:4.

Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003;1:58.

Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017;35(2):257-65.

Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, et al. Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA Dermatol. 2017;153(7):666-74.

Kawakami T, Hashimoto T. Disease Severity Indexes and Treatment Evaluation Criteria in Vitiligo. Dermatol Res Pract. 2011;2011:750342.

Majid I, Imran S. Ultrathin split-thickness skin grafting followed by narrowband UVB therapy for stable vitiligo: An effective and cosmetically satisfying treatment option. Indian J Dermatol Venereol Leprol. 2012;78:159-64.






Original Research Articles